Liu M, Lo EC, Wang G, Chow HF, et al. Identification of influenza polymerase inhibitors targeting polymerase PB2 cap-binding domain through virtual screening. Antiviral Res 2017 Jun 16. pii: S0166-3542(16)3058
Influenza A virus is the major cause of epidemics and pandemics worldwide. In this study, virtual screening was used to identify compounds interacting with influenza A polymerase PB2 cap-binding domain (CBD). With a database of 21,351 small molecules, 28 candidate compounds were obtained and four of them (225, 225D1, 426 and 426Br) were found to bind directly to PB2 CBD by surface plasmon resonance (SPR). The evaluation of compounds 426Br and 225 indicated that they could bind to PB2 CBD and inhibit influenza virus at low micromolar concentration. They were predicted to bind the cap binding site of the protein by molecular modeling and were confirmed by SPR assay using PB2 CBD mutants. These two compounds have novel scaffolds and could be further developed into lead compound for influenza virus inhibition.
See Also:
Latest articles in those days:
- Host Species Contribution to the Spatiotemporal Dynamics of the 2024-2025 H5N1 Epidemic in Italy 9 hours ago
- mRNA-based influenza vaccine expands the B cell response breadth in humans 9 hours ago
- Molecular surveillance and predictive risk modelling of avian influenza virus in wild birds in Egypt 9 hours ago
- Germany as a key transit hub for the emergence and spread of high pathogenicity avian influenza H5 clade 2.3.4.4b reassortants in Europe 1 days ago
- Degradation of ACSL3 by influenza A virus shifts unfolded protein response from antiviral defense to viral evasion 1 days ago
[Go Top] [Close Window]


